Semax Dosage Guide: Research Protocols and Administration

What Is Semax?

Semax is a synthetic heptapeptide derived from the ACTH(4-7) neuropeptide fragment - specifically the sequence Met-Glu-His-Phe with a Pro-Gly-Pro tripeptide appended to extend its stability and duration of action. This semax dosage guide draws on published research from institutions in Russia and Ukraine, where Semax has been used medically since the 1990s for conditions ranging from stroke recovery to cognitive decline. It was developed at the Institute of Molecular Genetics in Moscow during the 1980s.

The base structure comes from a small segment of adrenocorticotropic hormone (ACTH), but Semax carries none of the hormonal activity of its parent molecule. Instead, it exerts its effects primarily through the central nervous system - influencing BDNF (brain-derived neurotrophic factor), dopamine signaling, and neuroprotective pathways.

Outside of Russia, Semax is sold as a research compound and is not approved by the FDA for any therapeutic use. It remains one of the most-studied nootropic peptides in the literature, with over a hundred published papers examining its effects on cognition, neuroplasticity, and brain injury models.

For researchers interested in the broader cognitive peptide space, our guide on Selank peptide benefits covers a closely related compound that is often studied alongside Semax.

Semax Dosage Protocols

Semax dosage in published research varies significantly by route of administration, the specific variant used, and the target outcome. The figures below come from actual human and animal studies - not anecdotal reports.

Human Research Dosages

A 2021 comparison study published in Ceska a Slovenska Farmacie used standard Semax at 0.1 mg/kg as the reference compound in a passive avoidance memory paradigm. A pilot study on healthy adult subjects administered a total dose of 1.2 mg via a 1% intranasal solution. Daily dosages used in Russian clinical settings typically fall between 300-1200 mcg per day for cognitive applications.

Most intranasal protocols in the literature use:

• 300-600 mcg/day for general cognitive enhancement (2-3 drops of 0.1% solution per nostril, twice daily)
• 600-1200 mcg/day for neurological recovery models in clinical Russian studies
• 1200-3000 mcg/day for acute neuroprotection in stroke models (short-term protocols only)

For NA-Semax and NA-Semax Amidate, the acetylation and amidation modifications are believed to improve bioavailability - meaning lower doses may produce comparable effects to higher standard Semax doses. Many researchers apply a rough 2-3x potency adjustment when switching between variants, though no head-to-head human trials have confirmed this ratio.

Animal Study Reference Points

Rodent studies frequently use 50-150 mcg/kg administered intranasally or intraperitoneally. Neuroprotective effects in ischemia models were observed at approximately 100 mcg/kg. Gene expression changes in the hippocampus were detected within 20 minutes at these doses - a finding that highlights how rapidly Semax crosses into the CNS via the nasal route.

Keep in mind that animal-to-human dose conversions are not straightforward. Surface area scaling and metabolic differences make direct extrapolation unreliable.

Cycle Length

Russian medical protocols for cognitive applications typically use 10-14 day cycles with breaks of equal length. There is no established long-term safety data from controlled human studies, which is why most researchers use cyclical approaches rather than continuous dosing.

Intranasal vs Subcutaneous Administration

Semax was specifically designed for intranasal delivery. The nasal mucosa provides a direct pathway to the olfactory system and brainstem, allowing the peptide to bypass the blood-brain barrier more efficiently than subcutaneous injection for CNS-targeted effects.

Here is how the two routes compare in research contexts:

The intranasal route dominates in published Semax research and is specifically what most commercial nasal spray formulations are designed for. Subcutaneous injection remains an option some researchers explore, but there is far less human-applicable data supporting it for Semax specifically.

For a broader comparison of peptide delivery methods, see our guide on subcutaneous vs intramuscular injection and how oral vs injectable delivery compares across different peptides.

Semax Variants: Standard vs NA-Semax vs NA-Semax Amidate

Three main variants appear in the research literature and commercial supply chain. Understanding how they differ matters for anyone structuring a Semax-specific research protocol.

Standard Semax (Met-Glu-His-Phe-Pro-Gly-Pro)

The original compound. Studied in Russian clinical trials since the 1990s. Approved in Russia under the brand name Semax 0.1% nasal drops for memory improvement, cognitive decline, and as an adjunct treatment in cerebrovascular conditions. The half-life is short - minutes in plasma - but effects can persist for up to 24 hours due to downstream signaling cascades it initiates.

NA-Semax (N-Acetyl Semax)

An acetylated version of the parent compound. The N-terminal acetyl group protects the peptide from enzymatic degradation at the N-terminus, extending its active lifespan compared to standard Semax. Research on the acetylated form suggests improved stability without fundamentally altering the mechanism of action. Some researchers report the acetylated form may produce a stronger and longer cognitive effect per dose, though direct comparison trials are limited.

NA-Semax Amidate

This variant adds C-terminal amidation on top of N-terminal acetylation. The result is protection at both ends of the peptide chain - the most stable form commercially available. PeptidePick has a dedicated guide to NA-Semax Amidate that goes deeper on this variant.

Most researchers who have worked with all three forms consider NA-Semax Amidate the most potent per microgram, applying dose adjustments of roughly 50-70% compared to standard Semax when switching. But again - no controlled human trial has formally established this ratio.

Side-by-Side Variant Comparison

Semax Dosage Guide: Half-Life and Onset Timing

Semax has a short plasma half-life measured in minutes. This is common for small neuropeptides, which are rapidly degraded by circulating enzymes. But the short plasma half-life does not translate to a short effect window.

Research in rodent models shows cognitive improvement measurable within 15 minutes of intranasal administration. More importantly, the BDNF upregulation and gene expression changes Semax induces in the hippocampus and frontal cortex are persistent - lasting up to 24 hours after a single dose in some animal models.

This is why Semax does not need to be dosed multiple times per day at high quantities. The peptide acts as a trigger rather than a persistent ligand. It initiates downstream signaling cascades - BDNF, TrkB receptor activation, dopaminergic modulation - that outlast the peptide itself by many hours.

The Pro-Gly-Pro fragment appended to the base ACTH sequence is specifically responsible for this extended duration. Studies suggest this tripeptide tail resists degradation and may contribute independently to Semax's longer-than-expected biological activity relative to its short plasma presence.

Stacking Semax with Selank

The Semax-Selank combination is one of the most well-known nootropic peptide stacks and has a logical mechanistic basis. The two peptides complement rather than duplicate each other.

Semax primarily enhances cognitive output - focus, memory consolidation, and information processing speed. Its stimulatory effect on dopamine pathways can increase mental drive but may produce mild overstimulation in some research subjects, particularly at higher doses.

Selank works differently. It modulates GABAergic and serotonergic tone, producing anxiolytic effects without sedation. Research on Selank shows reductions in anxiety behavior in rodent models and improvements in memory under stress conditions - a distinct profile from Semax's more excitatory action. Our full article on Selank peptide benefits covers this in detail.

When combined, the stack theoretically addresses both the focus/drive dimension (Semax) and the calm/stress-resistance dimension (Selank). Both peptides have independently shown BDNF-upregulating properties, and some researchers expect additive effects on neuroplasticity from the combination.

There are no published clinical trials specifically examining the Semax-Selank combination. The rationale is built from mechanistic inference and the individual study profiles of each compound. A useful comparison of the two is available in our Semax vs Selank guide.

Typical combined research protocols use equal or near-equal doses - often 300 mcg of each intranasally in the morning, with Semax taken first and Selank 20-30 minutes later or simultaneously.

Reconstitution and Storage

Commercial Semax intended for nasal administration sometimes comes pre-formulated in an aqueous solution. Lyophilized powder requires reconstitution before use in any liquid administration protocol.

Reconstitution Steps

Standard reconstitution for intranasal use typically targets a 0.1% or 1% solution depending on the dosing goal. For a 0.1% solution (1 mg/mL), add 1 mL of bacteriostatic water per milligram of peptide. For a 1% solution (10 mg/mL), use 0.1 mL per milligram.

Use our free peptide reconstitution calculator to compute exact volumes for your specific vial size and target concentration. A step-by-step peptide reconstitution guide covers the full process from sterile technique to storage.

Storage Conditions

• Lyophilized powder: Store at -20°C for long-term stability. Stable at room temperature for short periods (days) during shipping.
• Reconstituted solution: Refrigerate at 2-8°C. Do not freeze. Use within 30 days of reconstitution.
• Light sensitivity: Store in amber vials or wrapped in foil. UV exposure degrades peptide bonds.
• Avoid contamination: Use sterile technique during reconstitution and dose extraction.

For more on maximizing peptide shelf life, our guide on how to store peptides covers all common peptide types including heat-sensitive variants.

Key Research Findings on Semax

The research base on Semax is concentrated primarily in Russian and Eastern European literature, which creates both depth and certain limitations for Western researchers accustomed to FDA-registered trial designs. That said, the mechanistic findings are consistent and replicated across multiple labs.

BDNF Upregulation

Multiple studies demonstrate that intranasal Semax rapidly increases BDNF levels in the hippocampus and frontal cortex. BDNF (brain-derived neurotrophic factor) is one of the most important regulators of neuronal survival, synaptic plasticity, and long-term memory formation. A 2001 study published in the Journal of Neurochemistry observed significant BDNF mRNA upregulation within 1 hour of intranasal administration in rats.

Neuroprotection in Ischemia Models

Semax has shown consistent neuroprotective effects in models of cerebral ischemia. At doses of 100 mcg/kg, it reduced infarct volume and improved behavioral recovery in rodent stroke models. These findings formed the basis for its clinical use in Russia as an adjunct therapy following ischemic stroke.

Cognitive and Memory Effects

The 2021 Ceska a Slovenska Farmacie study used Semax at 0.1 mg/kg as the reference compound in a passive avoidance memory paradigm - suggesting it is considered a reliable nootropic reference rather than an experimental outlier. Earlier Russian studies in healthy subjects showed improvements in attention, working memory, and learning rate at doses of 250-1000 mcg/kg.

Gene Expression Changes

Research has documented significant alterations in gene expression in the hippocampus and frontal cortex after Semax administration - including genes related to synaptic transmission, immune modulation, and neurotrophic signaling. These changes begin within 20 minutes of administration in animal models, consistent with the rapid CNS entry via the olfactory pathway.

For a broader overview of how peptides affect the nervous system and the standards used to evaluate research compounds, see our peptide quality verification guide and our article on peptide legality.

Where to Source Semax for Research

When sourcing any research peptide, third-party testing (COAs via HPLC and mass spectrometry) is the baseline standard. The companies below are approved sources used by PeptidePick's research network. For a wider comparison, see our best peptide companies guide.

Related Articles

• Selank Peptide Benefits: Anxiety, Memory, and BDNF Research
• Semax vs Selank: How They Compare for Cognitive Research
• NA-Semax Amidate: The Most Stable Semax Variant Explained
• How to Reconstitute Peptides: Step-by-Step Guide
• Free Peptide Reconstitution Calculator
• Best Peptide Companies: Ranked and Reviewed

Frequently Asked Questions